-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Vivos Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2024.
- Vivos Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.65M, a 27.3% increase year-over-year.
- Vivos Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$12.5M, a 34.8% increase year-over-year.
- Vivos Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$17.3M, a 30.9% increase from 2022.
- Vivos Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$25M, a 22.8% decline from 2021.
- Vivos Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$20.4M, a 69.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)